New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Jump to bottom

U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments #1081

Open

agitter opened this issue Jan 25, 2022 · 1 comment

Assignees

Labels

Collaborator

agitter commented Jan 25, 2022

This would be a good update for the therapeutics manuscript:

The U.S. health regulator revised on Monday the emergency use authorizations for COVID-19 antibody treatments from Regeneron (REGN.O) and Eli Lilly (LLY.N) to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.

From https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-restrict-use-regeneron-lilly-covid-antibody-drugs-wapo-2022-01-24/

agitter added the therapeutic label

agitter assigned rando2

Contributor

rando2 commented Jan 26, 2022

Excellent, thank you! We have so much to add to that manuscript!

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment